Concord Drugs Ltd - 538965 - Book Closure Intimation For The Purpose Of Annual General Meeting
Book Closure Intimation for the purpose of Annual General Meeting08-09-2021
08-09-2021
Concord Drugs Ltd - 538965 - Announcement under Regulation 30 (LODR)-Meeting Updates
Outcome of Meeting held on 08.09.202108-09-2021
Concord Drugs Ltd - 538965 - Outcome of Board Meeting (AGM on Sept 28, 2021)
Concord Drugs Ltd has informed BSE regarding Outcome of Board Meeting held on August 13, 2021.13-08-2021
Concord Drugs Ltd - 538965 - Unaudited Financial Results For The Quarter Ended 30.06.2021
Unaudited financial results for the quarter ended 30.06.202113-08-2021
Concord Drugs Ltd - 538965 - Board Meeting Intimation for Unaudited Financial Results For The Quarter Ended 30.06.2021
Concord Drugs Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/08/2021 ,inter alia, to consider and approve Unaudited financial results for the quarter ended 30.06.202102-08-2021
Concord Drugs Ltd - 538965 - Related Party Disclosure For The Quarter And Year Ended 31.03.2021
Related party Disclosure for the quarter and year ended 31.03.202128-07-2021
Concord Drugs Ltd - 538965 - Shareholding for the Period Ended June 30, 2021
Concord Drugs Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2021. For more details, kindly Click here21-07-2021
Concord Drugs Ltd - 538965 - Statement Of Investor Complaints For The Quarter Ended June 2021
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0000 Name of the Signatory :- Jyoti GoyalDesignation :- Company Secretary and Compliance Officer21-07-2021
Concord Drugs Ltd - 538965 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Compliance Certificate under Reg. 74(5) of SEBI (DP) Regulations, 201821-07-2021